Explore the most innovative targeted therapies revolutionizing cancer treatment. Discover how monoclonal antibodies and small-molecule inhibitors specifically act on cancer cells, minimizing damage to healthy tissues. This guide delves into advanced treatment options, including the latest research in immunotherapy and targeted drugs. Learn about the strategies offering renewed hope in the fight against various types of cancer, from breast to lung cancer.
Blocks proteins that encourage cancer growth
(+1)
Osimertinib is the current standard of care for the first-line treatment of advanced EGFR+ non-small cell lung cancer (NSCLC), demonstrating significant improvement in progression-free survival. Its design as a third-generation TKI allows it to target specific mutations, including T790M, making it highly effective in cases of resistance to previous therapies.
Treats chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
(+2)
Ibrutinib is an innovative targeted therapy that has transformed the treatment of several hematologic malignancies, such as mantle cell lymphoma and chronic lymphocytic leukemia. Its mechanism of action as a Bruton's tyrosine kinase (BTK) inhibitor offers an effective treatment option for patients with B-cell cancers.
Blocks signals to slow or stop cancer growth
Entrectinib is an innovative targeted therapy that addresses solid tumors with specific gene fusions, such as NTRK, ROS1, and ALK, providing a crucial treatment option for patients with these mutations. Its efficacy extends to pediatric patients as young as 1 month old, and its ability to cross the blood-brain barrier makes it valuable in treating brain metastases.
Highly effective at shrinking or stopping tumor progression
(+4)
Larotrectinib is an innovative targeted therapy that has revolutionized the treatment of certain cancers by being the first medicine approved for tumor-agnostic use. Its high selectivity as a TRK inhibitor makes it effective against solid tumors harboring NTRK gene fusions, offering a crucial treatment option for adult and pediatric patients with this specific genetic alteration.
Treats HER2-positive early breast cancer
(+2)
Trastuzumab is a pivotal targeted therapy that specifically acts on the HER2 protein, which is crucial for the growth of certain cancers. Its effectiveness in treating HER2-positive breast and stomach cancer has transformed the prognosis for many patients, offering a precise and effective treatment option.
All the rankings you can imagine
Thousands of verified votes to discover the best. Your vote here counts
Blocks BCL-2 protein
(+2)
Venetoclax is an innovative targeted therapy that acts as the first approved BCL-2 inhibitor, restoring apoptosis in cancer cells. Its effectiveness in treating chronic lymphocytic leukemia and acute myeloid leukemia establishes it as a significant advancement in hematologic oncology.
Used if cancer cells have a BRAF gene mutation
(+1)
This combination of targeted therapies has demonstrated superior efficacy in treating metastatic melanomas with BRAF V600E or V600K mutations, prolonging progression-free survival and overall survival. Its combined action on the BRAF and MEK pathways offers a more comprehensive and safer approach to combating tumors with these specific mutations.
Treats advanced or metastatic cancer
(+1)
This combination of targeted therapies has demonstrated significant efficacy in treating advanced melanoma with BRAF V600E/K mutations. It works by blocking key cell growth pathways, leading to a notable improvement in recurrence-free survival and overall survival for eligible patients. Its approval in 2018 marked a significant advancement in precision oncology.
Slows the growth of cancer cells
(+2)
Capmatinib is a crucial targeted therapy for non-small cell lung cancer with MET exon 14 skipping mutations, a difficult-to-treat condition. Its efficacy has been demonstrated in both clinical and real-world studies, offering an alternative with fewer side effects and better response than traditional chemotherapy.
Shrinks tumors and slows growth of NSCLC
(+3)
Tepotinib provides an effective targeted therapy for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. Its selective mechanism of action inhibits MET kinase activity, addressing a specific genetic alteration associated with poor prognosis in these patients.
Our ranking of the best targeted cancer therapies is based on an exhaustive compilation of public information and regulatory approvals. The aim is to provide a clear and useful overview of available treatment options, highlighting their characteristics and benefits.